Welcome to our dedicated page for UNITED STATES ANTIMONY SEC filings (Ticker: UAMY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on UNITED STATES ANTIMONY's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into UNITED STATES ANTIMONY's regulatory disclosures and financial reporting.
United States Antimony Corporation entered a Securities Purchase Agreement for a registered direct offering of 2,377,657 shares of common stock at $10.50 per share, for approximately $25 million in gross proceeds. The company expects net proceeds of $24,431,090.53 after the placement commission and a credit, with closing expected on or about October 14, 2025, subject to customary conditions.
The deal is being made off the company’s effective Form S-3 shelf and a Rule 462(b) S-3MEF. Titan Partners Group acted as exclusive placement agent with a 7% commission, subject to a credit. Separately, the company reduced its ATM capacity from $65,000,000 to $39,885,000 effective October 6, 2025, and as of October 10, 2025, cannot sell under the existing ATM prospectus supplement unless and until new offering documents are filed; the sales agreement remains in force.
United States Antimony Corporation is conducting a primary offering of 2,377,657 shares of common stock at $10.50 per share, for gross proceeds of $24,965,398.50. Titan Partners Group LLC is acting as exclusive placement agent on a best-efforts basis and will receive a 7.0% cash fee, with net proceeds to the company, after fees, reimbursable expenses and a closing credit, stated as $24,431,090.53.
Shares outstanding are expected to increase to 138,878,411 from 136,500,754 as of October 9, 2025. The company plans to use the funds to buy additional antimony and other critical mineral inventories, expand leasehold positions in Alaska and Montana, pursue acquisitions of critical mineral businesses or properties, potentially increase capacity at its Madero smelter in Mexico, and for general working capital. The company highlights that new investors will face immediate dilution, with pro forma net tangible book value moving to $1.00 per share versus the $10.50 offering price.
John M. Keane, a director of United States Antimony Corp (UAMY), filed an Initial Statement of Beneficial Ownership reporting no currently owned common shares and two time‑based awards granted on 08/19/2025. The filing shows 68,200 restricted stock units (RSUs) and a stock option covering 34,100 shares, each vesting one‑third on 08/19/2026, 08/19/2027, and 08/19/2028$4.26 and an expiration date of 08/19/2035. The RSUs convert to common stock at vesting; no direct common shares were reported.
United States Antimony Corporation entered into a Securities Purchase Agreement on October 6, 2025 for a registered direct offering of 3,500,000 shares of common stock at $7.50 per share. This will provide aggregate gross proceeds of approximately $26,250,000, with expected net proceeds of $25,558,750 after placement agent fees, a credit, and other expenses.
A.G.P./Alliance Global Partners acted as exclusive placement agent and will receive a 7% commission on the Offering’s gross proceeds, subject to a credit on the closing date. The Offering is being made under the company’s effective Form S-3 shelf registration statement and is expected to close on or about October 7, 2025, subject to customary conditions.
The company also adjusted its at-the-market (“ATM”) offering program. It reduced the ATM prospectus supplement’s aggregate offering price from $65,000,000 to $39,885,000. After accounting for $9,775,549 of prior ATM sales, the company may offer up to an additional $30,109,451 of common stock under the current ATM limit, while the underlying sales agreement with the agents remains in effect.
United States Antimony Corporation is offering 3,500,000 shares of common stock at $7.50 per share, for gross proceeds of $26.25 million. The deal is a best-efforts placement through A.G.P./Alliance Global Partners to a single purchaser, with the placement agent earning a 7.0% cash fee, partially offset by a credit.
The company expects net proceeds of approximately $25.4 million (about $25.56 million after fees, expenses and the credit), which it plans to use for working capital, buying additional antimony and other critical mineral inventory, expanding leasehold positions, potential acquisitions of critical mineral assets or companies, and possible expansion of its Madero smelter in Mexico above its 200‑ton‑per‑month capacity.
Shares outstanding were 131,092,887 as of October 3 2025 and are expected to be 134,592,887 after the offering. The company highlights that new investors will face immediate dilution, as pro forma net tangible book value would rise to $0.78 per share versus the $7.50 offering price.
United States Antimony Corporation filed a Form 8-K to share that, on October 6, 2025, it issued a press release announcing the pricing of a registered direct offering. The company is using this current report to make the information broadly available under Regulation FD, which is designed to ensure that all investors receive important company information at the same time.
The press release, dated October 6, 2025, is included as an exhibit to the report and is incorporated by reference. The company also clarifies that this disclosure is being treated as “furnished” rather than “filed,” which limits how it is used for certain legal liability purposes under the securities laws.
United States Antimony Corp (UAMY) director and officer Lloyd Bardswich reported a sale of 40,000 shares of the company's common stock on 09/29/2025 at a price of $6.44 per share. After the sale the filing shows beneficial ownership listed as 594.047 (as reported). The Form 4 was signed by the reporting person on 10/04/2025. No derivative transactions or additional purchases were disclosed.
Jeffrey Russell Fink, an officer and director of United States Antimony Corp (UAMY), reported two open-market dispositions on 10/03/2025. The filing shows a sale of 2,833 shares at $8.16 and a sale of 8,000 shares at $8.12. After those transactions the reported beneficial ownership totals are listed as 64,000 shares and 56,000, respectively, held in a direct capacity. The Form 4 is signed by the reporting person and indicates the transactions were not reported as part of a 10b5-1 plan. The filing provides a straightforward record of insider selling activity without additional commentary or explanatory notes.
UAMY filed a Form 144 notice for proposed sales of common stock.
The notice lists 2,833 shares (aggregate market value $23,103.12) and 8,000 shares (aggregate market value $64,960.80) to be sold through Merrill Edge on NYSE American, with an approximate sale date of October 3, 2025. The seller acquired 33,333 shares via restricted stock vesting on January 29, 2025 as compensation.
United States Antimony Corp (UAMY) director Michael A. McManus Jr. reported selling 50,000 shares of common stock on 10/01/2025 at a reported price of $7.316 per share. After the sale he beneficially owns 531,965 shares. The Form 4 was signed on 10/02/2025 and shows the transaction as a direct disposition by a director.